Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker (SYK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Stryker (SYK) Ahead of Earnings?

Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Stryker (SYK)

Mako is primed to "Stryke" in the second half of the year.

This Important Acquisition Is Starting to Pay Off for Stryker

Kalamazoo, Michigan, March 29, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Tuesday, April 27, 2021 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended March 31, 2021 and provide an operational update. Final operating results for the quarter ended March 31, 2021 will be released at 4:05 p.m. that day.

Stryker to host conference call on April 27, 2021

Air Products and Chemicals

Bristol-Myers

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

Mastercard

Oracle

In this article series, we provide a summary of upcoming ex-dividend dates. We present a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: March 30-April 12, 2021

Medtronic

This article series provides a summary of upcoming ex-dividend dates. We present a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: March 23-April 5, 2021

The FDA issued a safety advisory on Stryker Corporation's (NYSE: SYK) Scandinavian Total Ankle Replacement devices, also known as STAR Ankle, citing the risk of a plastic component breaking after surgical implantation. According to the FDA, the plastic component may break as soon as three to four years after the device is inserted, leading to surgery to repair or replace the device.

Stryker's STAR Ankle Replacement Device Gets FDA Safety Advisory

Stryker Corp (SYK) Presents at Cowen Healthcare Broker Conference Call - (Transcript)

Kalamazoo, Michigan, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 41st Annual Cowen Health Care Conference on Tuesday, March 2, 2021.

Stryker to participate in the 41st Annual Cowen Health Care Conference

KALAMAZOO, Mich., Feb. 16, 2021 /PRNewswire/ -- C2Dx Inc., a medical device company that invests in and refines the delivery of valuable, niche products to propel their growth, has acquired the T/Pump product line from Stryker. The T/Pump is the second product line for C2Dx, joining its...

C2Dx Acquires Stryker T/Pump

Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.

Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss

Stryker Corporation (SYK) CEO Kevin Lobo on Q4 2020 Results - Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of 10.20% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q4 Earnings Surpass Estimates

Shares of Stryker (NYSE:SYK) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 12.85% over the past year to $2.81, which beat the estimate of $2.55.

Recap: Stryker Q4 Earnings

Kalamazoo, Michigan, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2020 and 2021 outlook:

Stryker reports 2020 operating results and 2021 outlook

On Wednesday, January 27, Stryker (NYSE:SYK) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Stryker's Earnings Outlook

Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Baxter

Boston Scientific

Thermo Fisher Scientific

The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.

This Medical Device Maker Will Be Well Positioned Post COVID

Amgen

Cerner

Merck

Pfizer

UnitedHealth Group

Health Care Select Sector SPDR Fund

Politics is a wildcard that can negatively impact healthcare stocks. But there are still many top companies with great prospects to consider.

The 7 Best Healthcare Stocks to Buy for 2021

Ambarella

Brooks Automation

iRobot

Rockwell Automation

The robotics sector looks poised for a turnaround given the rapid shift to digitization and automation, making it wise to keep an eye on names like iRobot (IRBT), Ambarella (AMBA) and Stryker (SYK)

5 Robotics Stocks to Watch Amid Rising Shift to Automation

Stryker's (SYK) acquisition of OrthoSensor will help surgeons with real-time data-driven solutions and improve patient outcomes.

Stryker (SYK) Buys OrthoSensor to Grow in Sensor Technology

FANUC Corp

ReWalk Robotics

Trimble

Robotics stocks are poised to grow in 2021, calling for investment in Trimble (TRMB), Rockwell Automation (ROK), ReWalk Robotics (RWLK), Fanuc Corp (FANUY) and Stryker (SYK).

Robots Will Rule 2021: 5 Stocks Poised to Benefit

Kalamazoo, Michigan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Wednesday, January 27, 2021 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended December 31, 2020 and provide an operational update. Final operating results for the quarter ended December 31, 2020 will be released at 4:05 p.m. that day.

Stryker to host conference call on January 27, 2021

Stryker Corporation is a Dividend Champion with 27 consecutive years of dividend growth. Shares currently yield 1.03%. Stryker Corporation is poised to benefit from an aging and active population.

News for Stryker Stock (SYK)